Welcome to our dedicated page for Healthequity SEC filings (Ticker: HQY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The HealthEquity, Inc. (NASDAQ: HQY) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. HealthEquity is an administrator and custodian of health savings accounts (HSAs) and other consumer-directed benefits, and its filings offer detailed information on financial performance, governance, capital allocation, and risk factors associated with this business.
Investors can review current reports on Form 8-K, which HealthEquity uses to report material events such as quarterly financial results and outcomes of the annual meeting of stockholders. For example, an 8-K dated September 2, 2025 references a press release with financial results, while an 8-K dated June 26, 2025 describes shareholder voting on director elections, auditor ratification, and advisory approval of executive compensation, as well as authorization of a common stock repurchase program.
In addition to 8-Ks, HealthEquity’s periodic reports (such as Forms 10-K and 10-Q, when accessed through EDGAR) contain comprehensive financial statements, segment information, and discussions of revenue categories including service revenue, custodial revenue, and interchange revenue. These filings also describe non-GAAP measures like Adjusted EBITDA and non-GAAP net income, along with reconciliations to the most comparable GAAP measures and explanations of how management uses these metrics.
Filings further outline key risks, including competition in the healthcare and benefits administration industry, dependence on tax-advantaged HSAs and other consumer-directed benefits, cybersecurity and data privacy concerns, regulatory changes, and reliance on partners and third-party vendors. On Stock Titan, AI-powered tools can be applied to these documents to surface important sections, summarize lengthy disclosures, and help users quickly locate information on topics such as stock repurchase programs, custodial asset management, and governance decisions recorded in HealthEquity’s SEC reports.
HealthEquity, Inc. (HQY) – Form 4 insider filing
Director Stuart B. Parker reported the grant of 2,003 restricted stock units (RSUs) on 06/26/2025. The units were awarded at $0 cost and will vest in full at the company’s next annual shareholder meeting. Settlement in common shares is scheduled for 02/01/2028, or earlier upon a change-of-control, termination of service, or death, as defined in the 2024 Equity Incentive Plan.
Following the grant, Parker’s direct beneficial ownership rises to 21,835 HQY shares. No open-market purchases, sales, or derivative security exercises were reported, and Table II shows no option activity.
This filing reflects routine director equity compensation. While the transaction modestly increases insider alignment, the 2,003-share grant is immaterial relative to HealthEquity’s total shares outstanding and is unlikely to influence the company’s valuation or liquidity.
HealthEquity (NASDAQ:HQY) filed an 8-K disclosing results of its 26 June 2025 annual meeting and a significant capital-return action.
Shareholder votes: All nine directors were re-elected; PricewaterhouseCoopers LLP was ratified as auditor (82,962,314 for, 346,165 against); and FY-25 executive compensation was approved on an advisory basis (76,093,619 for, 3,218,477 against).
Capital allocation: The board authorized a new $300 million share-repurchase program, supplementing the existing $300 million authorization from August 2024. Repurchases may occur through open-market or privately negotiated transactions, including Rule 10b5-1 plans, and can be suspended at any time.
No other material disclosures were made.